🟢 At a Glance:

• 🎯 Director: John B. Bode
• 🧾 Form Type: SEC Form 4 (filed May 30, 2025)
• 🗓️ Grant Date: May 29, 2025
• 💰 Transaction: 30,000 stock options awarded
• ⚙️ Exercise Price: $8.62 (closing price on grant day)
• 💸 Cost to Acquire: $0 (compensation-based grant)
• 🗓️ Expiry: May 28, 2035

📜 Details of the Transaction

• 1 year from grant, OR
• 1 day before next AGM, OR
• Immediately upon change of control |
  | Form Type | SEC Form 4 – Insider Reporting |
  | Ownership Type | Direct (D) |

🤡 EduInvesting Take

“Zevra’s boardroom is so efficient, they just airdrop stock options with expiration dates longer than your EMI.”

This is classic non-employee director compensation theatre. No money exchanged. No shares purchased. Just 30,000 stock options as a ‘thank you’ for showing up to board meetings and approving clinical trials.

Also, let’s not pretend this is unusual — it’s standard across pharma boards. But 30,000 options with a 10-year expiry? That’s startup-level equity optimism.

🔍 Who is John B. Bode?

• Appears to be affiliated with Tribune Publishing (not exactly a biotech bro)
• Filed through Attorney-in-Fact — which means even the signature was outsourced
• Vesting tied to AGM, 1-year term, or acquisition event — all roads that lead to “board tenure = reward”

🧠 What You Should Watch For

• If ZVRA stock spikes above $8.62, Bode’s options are instantly valuable
• If stock crashes, no downside — he paid $0 anyway
• If change in control occurs, he vests early and walks

Heads he wins, tails he retires.

🏷️ Tags:

Zevra Therapeutics Insider Transaction, John B. Bode Form 4, SEC Director Stock Option Grant, ZVRA Insider Ownership, Biotech Board Compensation, EduInvesting Pharma Roast, Stock Options at Zero, Director Compensation Watch, May 2025 Form 4